Navigation Links
Huifeng Bio-Pharmaceutical (HFGB) to Release Second Quarter 2008 Earnings Results on August 15, 2008
Date:8/4/2008

XI'AN, China, Aug. 4 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio- Pharmaceutical Technology, Inc (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, today announced that it will release financial results second quarter 2008 which ended June 30 on Friday, August 15, 2008, after the US markets close.

Huifeng's earnings release and related materials will be posted on the investor's page of the company website, http://www.hfgb.cn .

About Huifeng Bio-Pharmaceutical Technology, Inc. (HFGB)

Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. For more information, please visit the company's web site at http://www.hfgb.cn/

For more information, please contact:

Dan Carlson, Primary Capital LLC

Email: DCarlson@PrimaryLLC.com

Kelly Black, CEO

Premier Media Services, Inc.

Tel: +1-480-649-8224


'/>"/>
SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status
2. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
3. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
4. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification
5. Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities
6. Huifeng Bio-Pharmaceutical (HFGB) to Release First Quarter 2008 Earnings Results on May 15, 2008
7. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
8. Sentry Enhances Offerings with Temperature-Controlled Custom Bio-Pharmaceutical Finishing Services
9. Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou
10. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... 6, 2011 Biodel Inc. (Nasdaq: BIOD ... and CEO of Biodel, will present a corporate update ... January 13, 2011 at 9:30 a.m. Pacific Time (12:30 ... the development of new follow-on formulations of its lead ...
... OAKS, Calif. and MONROVIA, Calif., Jan. 6, 2011 ... announced today that they will collaborate to develop XmAb ... CD19 and CD32b.  XmAb5871 is currently in late-stage preclinical ... Under the terms of the agreement, Amgen has ...
... DIEGO, Jan. 6, 2011 Ardea Biosciences, Inc. (Nasdaq: ... results from its Phase 2b study of RDEA594 in ... treatment of gout, allopurinol.  Allopurinol currently accounts for greater ... prescription medications; however, in controlled trials, only 30-40% of ...
Cached Biology Technology:Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 2Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 3Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 2Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 3Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 4Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 5Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 6Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 7
(Date:4/23/2014)... The shale gas boom has transformed the energy ... locations, it could cause conflict among the energy ... resources, say researchers. They add that degraded water ... adequate safeguards. The feature article appears in the ... , Meagan S. Mauter and colleagues point out ...
(Date:4/23/2014)... fiction, or simply cli-fi, is a newly coined term for ... warming. New research from University of Copenhagen shows how these ... simulate the potential consequences of climate change and imagine other ... scientific data on changes in the atmosphere; it is also ... the books we read and the films we see. And ...
(Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
Breaking Biology News(10 mins):How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3Loss of memory in Alzheimer's mice models reversed through gene therapy 2
... conducted at Western University (London, Canada) points to a ... (PTSD): utilising neurofeedback training to alter the plasticity of ... During neurofeedback, intentional control of one,s own ... brain-computer interface, which is able to represent graphically a ...
... those living with gastrointestinal disorders, such as ulcers or Crohn,s ... dietary changes. But what if one day treatment meant doing ... of inflamed or diseased tissues? That is where ... of Technology (MIT) are hoping their new study findings will ...
... Current pledges for greenhouse gas emission reductions are ... reach internationally agreed climate targets, according to new ... research teams coordinated by the International Institute for ... for Climate Impacts Research (PIK)., In the absence ...
Cached Biology News:Neurofeedback tunes key brain networks, improving subjective well-being in PTSD 2Manufacturing a new gut to treat GI diseases 2Continuing with pledge pathways to 2030 could push climate goals out of reach 2
... Synthesis Service provides you with ... knockdown any gene. We offer ... pairs with terminal dT nucleotides), ... lengths of your choice. Each ...
...
...
... Luminex 100 IS System is ideal for ... Beadlyte reagents. This system contains the new, ... by Luminex. The user can design specific ... The system has fully integrated graphing and ...
Biology Products: